Novome Biotechnologies

OverviewSuggest Edit

Novome Biotechnologies is a biotechnology company that engineers cell therapies for chronic diseases. Its platform enables controllable engraftment of genetically engineered microbial medicines in the gut for sustained therapies.

TypePrivate
Founded2016
Websitenovomebio.com

Latest Updates

Employees (est.) (Sept 2021)34(+7%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Novome Biotechnologies

Blake Wise

Blake Wise

CEO
Will Deloache

Will Deloache

CSO, Co-Founder
Weston Whitaker

Weston Whitaker

VP of Research, Co-Founder
Liz Shepherd

Liz Shepherd

Co-Founder
Zachary Russ

Zachary Russ

Co-Founder
Show more

Novome Biotechnologies Financials and Metrics

Summary Metrics

Founding Date

2016

Novome Biotechnologies total Funding

$38 m

Novome Biotechnologies latest funding size

$33 m

Time since last funding

2 years ago

Novome Biotechnologies investors

Novome Biotechnologies's latest funding round in January 2020 was reported to be $33 m. In total, Novome Biotechnologies has raised $38 m
Show all financial metrics

Novome Biotechnologies Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Novome Biotechnologies Online and Social Media Presence

Embed Graph

Novome Biotechnologies News and Updates

Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria

- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans -

Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer

McLean to lead the Company’s enteric hyperoxaluria program into Phase 1/2a clinical proof-of-concept, and to advance its Genetically Engineered Microbial Medicines (GEMMs) platform to address additional high unmet need diseases McLean to lead the Company’s enteric hyperoxaluria program into Phase 1/…

Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced the appointments of David N. Cook, PhD, and Zachary Hornby, both accomplished biotechnology executi…

Novome Biotechnologies Frequently Asked Questions

  • When was Novome Biotechnologies founded?

    Novome Biotechnologies was founded in 2016.

  • Who are Novome Biotechnologies key executives?

    Novome Biotechnologies's key executives are Blake Wise, Will Deloache and Weston Whitaker.

  • How many employees does Novome Biotechnologies have?

    Novome Biotechnologies has 34 employees.

  • Who are Novome Biotechnologies competitors?

    Competitors of Novome Biotechnologies include UCB, EMS Pharma and Alembic Pharmaceuticals.